Avidity Biosciences, Inc.(RNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RNA Avidity Biosciences, Inc.

Pre-Market Trading 10-24 08:18:28 EDT

45.40

-1.98

-4.18%

盘前46.00

+0.60+1.32%

08:09 EDT

High47.29	Low45.24	Vol793.58K
Open47.13	D1 Closing47.38	Amplitude4.33%
Mkt Cap5.32B	Tradable Cap4.39B	Total Shares117.12M
T/O36.20M	T/O Rate0.82%	Tradable Shares96.77M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"RNA","market":"US","secType":"STK","nameCN":"Avidity Biosciences, Inc.","latestPrice":45.4,"timestamp":1729713600000,"preClose":47.38,"halted":0,"volume":793584,"hourTrading":{"tag":"盘前","latestPrice":46,"preClose":45.4,"latestTime":"08:09 EDT","volume":160,"amount":7438,"timestamp":1729771748689},"delay":0,"floatShares":96765030,"shares":117121397,"eps":-2.935229,"marketStatus":"Pre-Market Trading","change":-1.98,"latestTime":"10-24 08:18:28 EDT","open":47.13,"high":47.29,"low":45.24,"amount":36197924.754816,"amplitude":0.043267,"askPrice":50.37,"askSize":100,"bidPrice":45,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.935229,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1729776600000},"marketStatusCode":1,"adr":0,"listingDate":1591934400000,"exchange":"NASDAQ","adjPreClose":45.4,"preHourTrading":{"tag":"盘前","latestPrice":46,"preClose":45.4,"latestTime":"08:09 EDT","volume":160,"amount":7438,"timestamp":1729771748689},"postHourTrading":{"tag":"盘后","latestPrice":45.4,"preClose":45.4,"latestTime":"19:47 EDT","volume":309372,"amount":14045633.236,"timestamp":1729727255786},"volumeRatio":0.8590477325258568,"impliedVol":0.7671,"impliedVolPercentile":0.4622},"requestUrl":"/m/hq/s/RNA","defaultTab":"news","newsList":[{"id":"2477360113","title":"ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2477360113","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477360113?lang=en_us&edition=fundamental","pubTime":"2024-10-23 04:01","pubTimestamp":1729627260,"startTime":"0","endTime":"0","summary":"LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct.  22, 2024  (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.(Nasdaq: PRQR) (“ProQR”), a company dedicated to changing lives through transformative RNA therapies ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/22/2967301/33039/en/ProQR-Announces-Proposed-Underwritten-Public-Offering-of-Ordinary-Shares.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNA","BK4139","BK4505","BK4588","BK4585"],"gpt_icon":0},{"id":"2477815152","title":"Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2477815152","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477815152?lang=en_us&edition=fundamental","pubTime":"2024-10-22 04:05","pubTimestamp":1729541103,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241021:nTUAC2NSQX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","RNA","BK4588","BK4505","BK4139"],"gpt_icon":0},{"id":"2477815418","title":"Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2477815418","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477815418?lang=en_us&edition=fundamental","pubTime":"2024-10-22 04:05","pubTimestamp":1729541100,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Oct. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. , a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates , today announced that onOctober 20, 2024,the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 421,600 shares of its common stock and 210,800 restricted stock units  to thirty-four  new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan . The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/MPQ_41DhqhHuW4qoOGYzoA--~B/aD0xODg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/d3ba411dafc5b9fe6b77b592275c9c79","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/MPQ_41DhqhHuW4qoOGYzoA--~B/aD0xODg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/d3ba411dafc5b9fe6b77b592275c9c79"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/avidity-biosciences-announces-inducement-grants-200500124.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avidity-biosciences-announces-inducement-grants-200500124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4112","BK4139","BK4505","LU2210149790.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4585","LU2095319765.USD","BK4588","RNA","NDAQ",".IXIC","LU2210150020.SGD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2477860906","title":"Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.","url":"https://stock-news.laohu8.com/highlight/detail?id=2477860906","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477860906?lang=en_us&edition=fundamental","pubTime":"2024-10-21 22:50","pubTimestamp":1729522237,"startTime":"0","endTime":"0","summary":"Shares of Korro Bio and Wave Life Sciences diverged Monday after an analyst argued Korro is the better way to play the RNA-editing space.","market":"us","thumbnail":"https://www.investors.com/wp-content/uploads/2017/11/Stock-drugVials-01-adobe-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2017/11/Stock-drugVials-01-adobe-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/korro-bio-wave-life-sciences-rna-editing/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4585","KRRO","GSK.UK","RNA","LU1829250122.USD","GSK","BK4588","BK4007","BK4505","BK4139","WVE","BK4532"],"gpt_icon":0},{"id":"2477859799","title":"TD Cowen Keeps Their Buy Rating on Avidity Biosciences (RNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2477859799","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477859799?lang=en_us&edition=fundamental","pubTime":"2024-10-21 19:45","pubTimestamp":1729511131,"startTime":"0","endTime":"0","summary":"In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Avidity Biosciences (RNA – Research Report), with a price target of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-avidity-biosciences-rna?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-avidity-biosciences-rna?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNA","TD","COWN"],"gpt_icon":0},{"id":"2477856170","title":"Avidity Biosciences price target raised to $78 from $56 at TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2477856170","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477856170?lang=en_us&edition=fundamental","pubTime":"2024-10-21 19:35","pubTimestamp":1729510514,"startTime":"0","endTime":"0","summary":"TD Cowen raised the firm’s price target on Avidity Biosciences (RNA) to $78 from $56 and keeps a Buy rating on the shares. The firm updated its mod...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avidity-biosciences-price-target-raised-to-78-from-56-at-td-cowen?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avidity-biosciences-price-target-raised-to-78-from-56-at-td-cowen?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TD","RNA","COWN"],"gpt_icon":0},{"id":"2476923858","title":"Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2476923858","media":"Blockhead","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476923858?lang=en_us&edition=fundamental","pubTime":"2024-10-18 20:00","pubTimestamp":1729252847,"startTime":"0","endTime":"0","summary":"The three-horse race to treat a devastating form of muscular dystrophy is now down to two. And Avidity Biosciences is feeling bullish.","market":"hk","thumbnail":"https://www.investors.com/wp-content/uploads/2024/10/TECH1_muscdys_101824_adobe-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2024/10/TECH1_muscdys_101824_adobe-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/avidity-biosciences-fshd-dm1-dmd-treatment-rna/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["LU0306806265.USD","ARWR","LU0203202063.USD","LU1430594728.SGD","LU0097036916.USD","LU0198837287.USD","LU1718418525.SGD","LU0306807586.USD","IE00B4R5TH58.HKD","IONS","LU0689472784.USD","ALNY","LU1670710588.SGD","LU0096364046.USD","LU0225284248.USD","BK4588","FULC","IE0009355771.USD","LU0823416689.USD","BK4581","IE00B2B36J28.USD","LU0114720955.EUR","LU0640476718.USD","03165","LU1074936037.SGD","LU1670711123.USD","LU1670710661.SGD","BMY","LU0820561909.HKD","LU0471298777.SGD","LLY","BK4505","LU0882574139.USD","LU1032466523.USD","IE00BFTCPJ56.SGD","LU0466842654.USD","BK4139","LU0456855351.SGD","LU0985481810.HKD","LU2133065610.SGD","BK4585","LU2242652126.USD","LU1064131342.USD","RHHBY","LU0385154629.USD","LU1670711040.USD","LU1069344957.HKD","SRPT","RNA","LU0820561818.USD"],"gpt_icon":1},{"id":"2476117018","title":"Positive Outlook for Wave Life Sciences Driven by Promising RNA Editing Data and Strategic Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2476117018","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476117018?lang=en_us&edition=fundamental","pubTime":"2024-10-17 23:15","pubTimestamp":1729178153,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Salim Syed has maintained their bullish stance on WVE stock, giving a Buy rating today. Salim Syed’s rating is based on s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/positive-outlook-for-wave-life-sciences-driven-by-promising-rna-editing-data-and-strategic-opportunities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/positive-outlook-for-wave-life-sciences-driven-by-promising-rna-editing-data-and-strategic-opportunities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4505","RNA","BK4585","BK4588"],"gpt_icon":0},{"id":"2476177020","title":"Wave Life Sciences Shares Surge After RNA Editing Discovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2476177020","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476177020?lang=en_us&edition=fundamental","pubTime":"2024-10-17 22:56","pubTimestamp":1729176980,"startTime":"0","endTime":"0","summary":"Oct. 17, 2024 The stock of Wave Life Sciences , a global biotechnology company, has risen by 74% on Wednesday after a major development. The company has scored a landmark by delivering the essential therapeutic RNA editing in human trials for the first time. This finding may open the door for treatment of many other genetic disorders like Alpha-1 Antitrypsin Deficiency .Wave's RNA editing technology appears to have highly potential for the treatment of AATD, a genetic disorder with potential life threatening and implicating the lungs and liver. As recently demonstrated in a Phase I and II concept trial, a single dose of WVE-006, Wave's RNA editing based therapy, boosted the levels of wild type alpha-1 antitrypsin protein which is severely low in patients suffering from AATD. It may be possible that this increase will help to decrease the incidence of AATD associated lung and liver diseases.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/edwUWhC.nHgg_53GeQ_FbA--~B/aD0zNjE7dz0zNjE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/4ca4270a74ed136b7221b2ecade1aca8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/edwUWhC.nHgg_53GeQ_FbA--~B/aD0zNjE7dz0zNjE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/4ca4270a74ed136b7221b2ecade1aca8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wave-life-sciences-shares-surge-145620795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RNA","BK4007","WVE"],"gpt_icon":0},{"id":"2476188346","title":"Promising Potential of ADAR RNA Editing Fuels Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2476188346","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476188346?lang=en_us&edition=fundamental","pubTime":"2024-10-17 07:45","pubTimestamp":1729122321,"startTime":"0","endTime":"0","summary":"Chardan Capital analyst Keay Nakae has reiterated their bullish stance on ADVM stock, giving a Buy rating on October 14. Keay Nakae has given his B...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-potential-of-adar-rna-editing-fuels-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-potential-of-adar-rna-editing-fuels-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNA"],"gpt_icon":0},{"id":"2476923821","title":"Stifel says early WVE-006 data de-risks DNA editing approaches like Beam’s ‘302","url":"https://stock-news.laohu8.com/highlight/detail?id=2476923821","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476923821?lang=en_us&edition=fundamental","pubTime":"2024-10-17 02:00","pubTimestamp":1729101636,"startTime":"0","endTime":"0","summary":"Stifel analyst Dae Gon Ha notes that initial Wave Life Sciences’ (WVE) WVE-006 data supports the mechanism of their A-to-I RNA editing in alpha-1 a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/stifel-says-early-wve-006-data-de-risks-dna-editing-approaches-like-beams-302?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/stifel-says-early-wve-006-data-de-risks-dna-editing-approaches-like-beams-302?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["WVE","BK4588","RNA","BK4127","DNA","BK4585","BK4109","BK4139","BK4505","SF","BK4007"],"gpt_icon":0},{"id":"2476094248","title":"Wave Life Sciences Stock Climbs on RNA Editing Progress -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2476094248","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476094248?lang=en_us&edition=fundamental","pubTime":"2024-10-17 01:16","pubTimestamp":1729098960,"startTime":"0","endTime":"0","summary":"Wave Life Sciences shares soared more than 70% on Wednesday after the biotech firm said it had successfully edited the RNA of patients with a genetic disorder that can lead to lung or liver disease.The early-stage data furnishes proof that Wave's approach to editing RNA could work in other diseases, and came as a pleasant surprise given that some analysts had expected that multiple doses of the treatment, codenamed WVE-006, would be needed to have a pronounced effect.Wave shares jumped to $14.65 in midday trading, up from $8.56 at Tuesday's close, at one point adding $993 million in market value. Wave shares have more than doubled over the past 12 months.This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","BK4585","WVE","BK4505","BK4139","BK4588","BK4007","LU2065732104.USD","RNA","PRGS"],"gpt_icon":0},{"id":"2476949928","title":"RNA-Editing Stocks Soar on Wave Life’s Breakthrough Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2476949928","media":"Bloomberg","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476949928?lang=en_us&edition=fundamental","pubTime":"2024-10-17 00:57","pubTimestamp":1729097853,"startTime":"0","endTime":"0","summary":" -- Companies developing RNA-editing therapies are rallying Wednesday after breakthrough data from a clinical trial showed the technology’s promise as a treatment.Wave Life Sciences Ltd. said it achieved so-called proof-of-mechanism in a single-dose trial of its potential treatment for a genetic disorder that causes lung and liver diseases. Its stock surged as much as 82% to the highest level since September 2020, adding about $960 million to the drug developer’s market value.Wall Street praised the potential for Wave Life’s drug as early efficacy results surpassed analysts’ expectations. While it could take years for the drug to come to market, the data represents a landmark for the RNA-editing space — as the earliest human data for any RNA editing therapy and a validation for the technology.“This is the first time we’ve seen it in humans actually do what we think it’s doing” said Madison El-Saadi, an analyst at B Riley Securities. “The fact that we see this with just one dose, it is ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mnAj69ss2.e.1Y8pLNbhvQ--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/bloomberg_markets_842/1151cdb5995681b26f60a71cd99b21ed","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mnAj69ss2.e.1Y8pLNbhvQ--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/bloomberg_markets_842/1151cdb5995681b26f60a71cd99b21ed"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rna-editing-stocks-soar-wave-165733064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","WVE","RNA"],"gpt_icon":0},{"id":"2476945072","title":"Wave Life Sciences Just Edited RNA. Why Its Key Rival, Korro Bio, Skyrocketed.","url":"https://stock-news.laohu8.com/highlight/detail?id=2476945072","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476945072?lang=en_us&edition=fundamental","pubTime":"2024-10-16 23:39","pubTimestamp":1729093185,"startTime":"0","endTime":"0","summary":"Shares of Wave Life Sciences surged Wednesday after the company announced \"impressive\" proof-of-concept results for its new technology.","market":"us","thumbnail":"https://www.investors.com/wp-content/uploads/2024/10/Stock-WaveLifeSciences-01-shutt-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2024/10/Stock-WaveLifeSciences-01-shutt-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/wave-life-sciences-rna-editing-alpha-1-antitrypsin/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["WVE","BK4139","KRRO","BK4007","RNA"],"gpt_icon":0},{"id":"2475911940","title":"Wave Life Sciences: Buy Rating Affirmed on Promising RNA Editing Platform Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2475911940","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475911940?lang=en_us&edition=fundamental","pubTime":"2024-10-16 22:45","pubTimestamp":1729089909,"startTime":"0","endTime":"0","summary":"Joseph Schwartz, an analyst from Leerink Partners, reiterated the Buy rating on Wave Life Sciences (WVE – Research Report). The associated price ta...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wave-life-sciences-buy-rating-affirmed-on-promising-rna-editing-platform-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wave-life-sciences-buy-rating-affirmed-on-promising-rna-editing-platform-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNA"],"gpt_icon":0},{"id":"2475992369","title":"Wave Life Sciences Advances in RNA Editing Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2475992369","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475992369?lang=en_us&edition=fundamental","pubTime":"2024-10-16 20:57","pubTimestamp":1729083473,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Wave Life Sciences ( ($WVE) ). Wave Life Sciences Ltd. has achieved a breakthrough in therapeutic RNA editing, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/wave-life-sciences-advances-in-rna-editing-innovation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/wave-life-sciences-advances-in-rna-editing-innovation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","RNA","BK4588","BK4505","BK4139"],"gpt_icon":0},{"id":"2475225993","title":"BRIEF-Wave Life Sciences Announces First-Ever Therapeutic RNA Editing In Humans Achieved In Restoraation-2 Trial Of WVE-006 In Alpha-1 Antitrypsin Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2475225993","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475225993?lang=en_us&edition=fundamental","pubTime":"2024-10-16 20:31","pubTimestamp":1729081866,"startTime":"0","endTime":"0","summary":"Oct 16  - WAVE Life Sciences Ltd   :   * WAVE LIFE SCIENCES ANNOUNCES FIRST-EVER THERAPEUTIC RNA EDITING IN HUMANS ACHIEVED IN RESTORAATION-2 TRIAL OF WVE-006 IN ALPHA-1 ANTITRYPSIN DEFICIENCY   * WAVE LIFE SCIENCES LTD: EXPECTS TO SHARE MULTIDOSE DATA FROM RESTORAATION-2 TRIAL IN 2025Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RNA","WVE"],"gpt_icon":0},{"id":"2475995355","title":"Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2475995355","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475995355?lang=en_us&edition=fundamental","pubTime":"2024-10-16 20:30","pubTimestamp":1729081800,"startTime":"0","endTime":"0","summary":"Achieved proof-of-mechanism for Wave’s RNA editing platform; restoring levels of wild-type (edited) M-AAT that are consistent with the heterozygous “MZ” genotype with low risk of AATD lung and liver d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/16/2964053/0/en/Wave-Life-Sciences-Announces-First-Ever-Therapeutic-RNA-Editing-in-Humans-Achieved-in-RestorAATion-2-Trial-of-WVE-006-in-Alpha-1-Antitrypsin-Deficiency.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4585","BK4139","WVE","BK4505","RNA","BK4588"],"gpt_icon":0},{"id":"2475083993","title":"Alnylam submits regulatory application to EMA for vutrisiran for ATTR-CM","url":"https://stock-news.laohu8.com/highlight/detail?id=2475083993","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475083993?lang=en_us&edition=fundamental","pubTime":"2024-10-16 20:27","pubTimestamp":1729081624,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals announced the submission of a Type II Variation to the European Medicines Agency EMA for vutrisiran, an investigational RNA...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alnylam-submits-regulatory-application-to-ema-for-vutrisiran-for-attr-cm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alnylam-submits-regulatory-application-to-ema-for-vutrisiran-for-attr-cm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4139","CM","BK4207","RNA","BK4585","BK4588"],"gpt_icon":0},{"id":"2475899314","title":"Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2475899314","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475899314?lang=en_us&edition=fundamental","pubTime":"2024-10-16 20:25","pubTimestamp":1729081500,"startTime":"0","endTime":"0","summary":"Event will highlight WVE-006 for AATD and Wave’s rapidly advancing, wholly owned pipeline of RNA medicines, including introducing new RNA editing programs and new preclinical data for WVE-007 INHBE pr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/16/2964031/0/en/Wave-Life-Sciences-Announces-Upcoming-Virtual-Research-Day-on-Wednesday-October-30-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNA","BK4505","BK4588","BK4585","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aviditybiosciences.com","stockEarnings":[{"period":"1week","weight":-0.0723},{"period":"1month","weight":0.0437},{"period":"3month","weight":0.0152},{"period":"6month","weight":0.8637},{"period":"1year","weight":7.6476},{"period":"ytd","weight":4.0166}],"compareEarnings":[{"period":"1week","weight":-0.0074},{"period":"1month","weight":0.0146},{"period":"3month","weight":0.0735},{"period":"6month","weight":0.1372},{"period":"1year","weight":0.3644},{"period":"ytd","weight":0.216}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.003796},{"month":2,"riseRate":0.75,"avgChangeRate":0.142853},{"month":3,"riseRate":0.5,"avgChangeRate":0.008776},{"month":4,"riseRate":0.25,"avgChangeRate":-0.099421},{"month":5,"riseRate":0.5,"avgChangeRate":-0.010872},{"month":6,"riseRate":1,"avgChangeRate":0.162259},{"month":7,"riseRate":0.4,"avgChangeRate":-0.025313},{"month":8,"riseRate":0.6,"avgChangeRate":0.033831},{"month":9,"riseRate":0.4,"avgChangeRate":-0.044821},{"month":10,"riseRate":0,"avgChangeRate":-0.107567},{"month":11,"riseRate":0.5,"avgChangeRate":0.133687},{"month":12,"riseRate":0.75,"avgChangeRate":0.245496}],"exchange":"NASDAQ","name":"Avidity Biosciences, Inc.","nameEN":"Avidity Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avidity Biosciences, Inc.(RNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Avidity Biosciences, Inc.(RNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Avidity Biosciences, Inc.,RNA,Avidity Biosciences, Inc.股票,Avidity Biosciences, Inc.股票老虎,Avidity Biosciences, Inc.股票老虎国际,Avidity Biosciences, Inc.行情,Avidity Biosciences, Inc.股票行情,Avidity Biosciences, Inc.股价,Avidity Biosciences, Inc.股市,Avidity Biosciences, Inc.股票价格,Avidity Biosciences, Inc.股票交易,Avidity Biosciences, Inc.股票购买,Avidity Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avidity Biosciences, Inc.(RNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Avidity Biosciences, Inc.(RNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction